Safety and Dose Finding Study of Different MOD-4023 Dose Levels Compared to Daily r-hGH Therapy in Pre-pubertal Growth Hormone Deficient Children

Trial Profile

Safety and Dose Finding Study of Different MOD-4023 Dose Levels Compared to Daily r-hGH Therapy in Pre-pubertal Growth Hormone Deficient Children

Completed
Phase of Trial: Phase II

Latest Information Update: 31 Jan 2017

At a glance

  • Drugs Somatropin (Primary)
  • Indications Somatotropin deficiency
  • Focus Therapeutic Use
  • Sponsors OPKO Health; PROLOR Biotech
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 31 Jan 2017 Results published in the Journal of Clinical Endocrinology and Metabolism
    • 06 Sep 2016 According to an OPKO Health media release, results of complete 24 months from this study will be presented at the 55th Annual Meeting of the European Society for Paediatric Endocrinology (ESPE).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top